Bevacizumab and Cetuximab With or Without Irinotecan in Treating Patients With Irinotecan-Refractory Metastatic Colorectal Cancer

NCT00077298 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

70

Enrollment

NIH

Sponsor class

Conditions

Recurrent Colon Cancer
Recurrent Rectal Cancer
Stage IVA Colon Cancer
Stage IVA Rectal Cancer
Stage IVB Colon Cancer
Stage IVB Rectal Cancer

Interventions

BIOLOGICAL: cetuximab
BIOLOGICAL: bevacizumab
DRUG: irinotecan hydrochloride
OTHER: laboratory biomarker analysis

Sponsor

National Cancer Institute (NCI)